Since hepatic FOXA3 is markedly reduced in obesity and MASH, targeting hepatic FOXA3 may be a useful strategy for the treatment of obesity and MASH. The gene discussed is FOXA3; the disease is metabolic dysfunction-associated steatohepatitis.